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incidence (CI) of grade II-IV acute GVDHwhile accounting for
competing events, at day +100 was 34.2% (n¼6) and 46.2%
(n¼8) at day +180. The CI for grade III-IV acute GVHD was
22% (n¼4) at day +100, and 29.4% (n¼5) at day +180. CI of
chronic GVHD (cGVHD) was 50.5% at one year. CI of limited
and extensive chronic GVHD was 22.1% (n¼3) and 29.2%
(n¼4), respectively at one year. The CI of relapse was 11.7%
(n¼2) at one year. The non-relapse mortality (NRM) was 0%
at day +100 and 14.7% (n¼2) at one year. Causes of death
include disease relapse (n¼2), GVHD (n¼2), and accident
(n¼1). The overall and progression free survival at one year is
73.5%. Our limited, retrospective data show encouraging
relapse and NRM rates with TLI/ATG-based NMA condi-
tioning, but with higher than previously reported rates of
acute and chronic GVHD, underscoring the need for novel
strategies designed to effectively prevent GVHD.
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Background: Donor T cell activation in response to alloanti-
gens presented by host antigen presenting cells (APC) is
a critical step in the pathophysiology of Graft Versus Host
Disease. The macrolide Azithromycin (Azi) is studied in lung
transplant and allogeneic hematopoietic cell transplant (HCT)
recipients to decrease graft rejection and progression of lung
injury, respectively.WenowtestedwhetherAzi plays a role in
the modulation of adaptive immune responses by deter-
mining its effects on alloantigen-dependent T cell activation.
Methods: In vitro: Mixed lymphocyte reactions (MLR) using
C57BL/6 (H2b) T cells as responders and B6D2F1 (H2bd) or
BALB/c (H2d) splenocytes as stimulators, as well as TCR
dependent, alloantigen-independent CD3/CD28 or lectin-
type stimulation (Concavalin) assays of C57BL/6 Tcells were
performed in the absence or presence of Azi at varying
concentrations 5mg/ml, 10mg/ml, 20mg/ml, 50mg/ml. T cell
proliferation was assessed by 3HT-uptake. T cells were phe-
notyped and supernatant was tested for cytokine expression.
In vivo: B6D2F1 were pretreated for 2 weeks with Azi at
a dose of 3mg/ml drinking water or received untreated water
as control. Then, animals were conditioned with 12Gy TBI
and transplanted with 4X10E6 bone marrow cells and
6X10E6 splenocytes from allogeneic C57BL/6 donors.Azithromycin (mg/ml)
0 5
MLR cpm 20053  1041 17497  12
IFNg (pg/ml) 590.5  59.9 476.0  42
TNF (pg/ml) 139.1  8.0 114.2  5.
IL-2 (pg/ml) 27.0  0.6 23.4  1.
IL-10 (pg/ml) 115.5  8.8 99.1  14
IL-17 (pg/ml) 24.7  0.9 19.3  3.
IL-4 (pg/ml) d d
IL-6 (pg/ml) 169.3  8.3 139.6  16
%CD4+FOXP3+ 2.5  0.1 2.9  0.
Con A cpm 61791  4529 64350  36
CD3/CD28 cpm 54868  1873 51182  20
cpm ¼ counts per minute
d ¼ below assay sensitivity
* p < 0.05
** P < .01Recipients continued to receive Azi-supplemented or
untreated water, and on day+7, splenic T cell expansion and T
cell phenotyping were done.
Results: AlloreactiveTcell proliferation invitro showedanAzi
dose-dependent decline at 96 hours along with reductions in
TNF, IFNg, IL-2, IL-6, L-10, IL-17. Interestingly, a signiﬁcant
relative expansion of CD4+FOXP3+ T cells (Tregs) within the
CD4+ T cell fraction was observed with increasing Azi-levels
from2.50.1% (0mg/ml) to 5.00.2% (50mg/ml).Nodifferences
in T cell proliferation were seen when T cell stimulation
occurredAPC-independenteither via ConcavalinAor via CD3/
CD28 except for slight suppression at Azi 50 mg/ml. In vivo,
whencompared to controls, pretreatmentwithAzi resulted in
decreased splenic expansion of both CD4+ T cells
(2.1X10E60.2 vs. 4.3X10E60.6, P < .01) and CD8+ T cells
(4.9X10E60.5 vs. 6.4X10E60.4, P < .05) along with a slight
and non-signiﬁcant increase of Tregs (1.5 0.3% vs 1.10.1%).
Conclusion: Azithromycin suppresses alloreactive T cell re-
sponse in vitro and in vivo, paralleled by the induction of Tregs,
supporting its use in lung transplantation and allogeneic HCT.463
Association of Comorbidity Scoring with Outcome in
Patients with Chronic Graft Versus Host Disease
William A. Wood 1, Xiaoyu Chai 2, Daniel J. Weisdorf 3,
Paul J. Martin 4, Corey Cutler 5, Yoshihiro Inamoto 6,
Daniel Wolff 7, Steven Z. Pavletic 8, Joseph Pidala 9,
Jeanne Palmer 10, Mukta Arora 11, Sally Arai 12,
Madan H. Jagasia 13, Barry Storer 6, Stephanie J. Lee 14,
Sandra Mitchell 15. 1 Department of Medicine, Division of
Hematology/Oncology, Lineberger Comprehensive Cancer
Center, University of North Carolina at Chapel Hill, Chapel Hill,
NC; 2 Clinical Research Division, Fred Hutchinson Cancer
Research Center, Seattle, WA; 3Masonic Cancer Center,
University of Minnesota, Minneapolis, MN; 4 Fred Hutchinson
Cancer Research Center, Seattle, WA; 5Department of Medical
Oncology, Dana-Farber Cancer Institute, Boston, MA; 6Division
of Clinical Research, Fred Hutchinson Cancer Research Center,
Seattle, WA; 7Department of Hematology and Clinical
Oncology, University of Regensburg, Regensburg, Germany;
8NCI Experimental Transplantation and Immunology Branch,
National Institute of Health NIH, Bethesda, MD; 9Hematology/
Oncology, Mofﬁtt Cancer Center, Tampa, FL; 10Department of
Hematology and Oncology, Medical College of Wisconsin,
Milwaukee, WI; 11Hematology, Oncology and Transplant,
University of Minnesota, Minneapolis, MN; 12 Stanford
University, Stanford, CA; 13Hematology/Oncology, Vanderbilt
University Medical Center, Nashville, TN; 14 Clinical Transplant
Research, Fred Hutchinson Cancer Research Center, Seattle,10 20 50
37ns 15340  1157* 12902  1317** 5637  215**
.6 363.6  18.6** 218.7  19.2** 37.05  4.5**
4* 115.4  5.6* 104.6  2.5** 71.3  3.7**
2 23.4  0.2 25.2  1.0 18.3  1.2**
.4 98.9  4.3 65.0  6.8** 19.7  3.5**
3 17.6  1.1 9.4  1.5** 4.2  0.3**
d d d
.3 120.7  11.7* 96.7  9.4** 49.9  5.3**
1 2.7  0.3 4.2  0.2** 5.0  0.1**
92 66065  3174 40012  2016*
71 51351  1447 51659  862 42002  633**
